EHA Unplugged

Explore the latest EHA guidelines on chronic lymphocytic leukemia (CLL) and Richter transformation with key guideline authors Prof Barbara Eichhorst, hematologist at University Hospital Cologne (Germany), and Prof Paolo Ghia, Director of the CLL Program at Università Vita-Salute San Raffaele (Milan, Italy). 

For the first time, the guidelines no longer recommend chemoimmunotherapy when targeted options are available, based on two key advances: the approval of acalabrutinib plus venetoclax with or without obinutuzumab for frontline CLL, and the approval of pirtobrutinib, a non-covalent BTK inhibitor, for relapsed/refractory disease—particularly after prior covalent BTK inhibitor treatment. The guests also make clear that patient selection matters, including TP53 status, IGHV status, comorbidities, co-medications, safety profile, and patient preferences.  

Further, the experts highlight a landmark change in how the recommendations were developed: for the first time, patients and patient advocates participated as authors, bringing a patient-centred perspective to treatment decisions, active surveillance, and supportive care.  

Tune in for practical insights into personalized CLL management, fixed-duration targeted therapy, treatment sequencing, and the challenges of Richter transformation.

Guests: 

Prof Barbara Eichhorst

University of Cologne, Cologne, Germany

Prof Paolo Ghia

Università Vita-Salute San Raffaele, Milano, Italy

Host:   

Isabel Olivera-Martínez, PhD,  

Medical Writer for EHA 

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Stay up to date with the latest EHA guidelines on Hodgkin lymphoma. In this episode of EHA Unplugged, key guideline authors Prof. Dennis Eichenauer and Prof. Igor Aurer discuss the evidence reshaping the management of classic Hodgkin lymphoma. 

The discussion highlights the guideline’s central shift: the integration of targeted therapies—brentuximab vedotin and PD-1 inhibitors such as nivolumab—into frontline treatment. The experts explain updated approaches to staging and risk assessment, PET-guided treatment in early-stage disease, BrECADD for younger patients with advanced disease, and nivolumab–AVD for older patients, alongside recommendations for relapsed or refractory disease and autologous stem cell transplantation. 

They also consider survivorship, late effects, and the realistic prospects for chemotherapy-free, immune-based approaches.  

Tune in for practical, evidence-based insights into improving outcomes while reducing long-term toxicity in Hodgkin lymphoma. 

Guests: 

Prof. Dennis Eichenauer: University of Cologne, Germany;  

First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf, German Hodgkin Study Group, University of Cologne, Cologne, Germany 

Prof. Igor Aurer: University Hospital Centre Zagreb, and Medical School, University of Zagreb, Zagreb, Croatia 

Host:   

Nabil Dorkhom, MD / EHA Head of Education 

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, Prof Gianluca Gaidano, recipient of the EHA2026 Diversity, Equity and Inclusion Award, explores how promoting equity, inclusion, and access to care has shaped his work within EHA and beyond. He reflects on educational initiatives in underrepresented regions, including Africa, the Middle East, Asia, and South America, and explains how international collaborations can help expand access to medical knowledge, advanced diagnostics, and innovative therapies.  

The discussion explores the difference between drug availability and true patient access, the role of education and patient advocacy in reducing disparities, and how partnerships with local hematology communities can strengthen clinical practice. Prof Gaidano also shares examples from countries such as Bangladesh, Iraq, and Albania, highlighting progress in access to diagnostics, treatments, and specialist training. Listen now for insights into how to contribute to building a more equitable future for hematology.  

Guest: Prof Gianluca Gaidano,  Amedeo Avogadro University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara, Italy  

Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer  

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, Professor Josep-María Ribera, recipient of the EHA2026 Clinical Excellence Award, reflects on his career dedicated to adult acute lymphoblastic leukemia (ALL) and the advances that have transformed patient outcomes. He discusses the evolution of treatment for Philadelphia chromosome-positive ALL, from poor survival rates to highly effective targeted and immunotherapy-based approaches, and explains how tyrosine kinase inhibitors, blinatumomab, and chemotherapy-sparing strategies are reshaping care.

The discussion also explores the growing role of measurable residual disease (MRD) monitoring and genetic risk stratification in treatment decision-making, including identifying which patients can safely avoid allogeneic stem cell transplantation. Professor Ribera highlights the impact of collaborative research through PETHEMA, EWALL, and EHA, and shares his perspective on the future of hematology. Listen now for insights into the progress of ALL treatment and a message of optimism for patients and clinicians alike.

Guest: Prof Josep-María Ribera

Josep Carreras Leukemia Research Institute (IJC) and Universitat Autònoma de Barcelona, Spain

Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer  

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, Dr Nico Gagelmann, recipient of the 2026 Young EHA Award, discusses his career in stem cell transplantation and the values that have shaped his work. He explains how multidisciplinary care, patient selection, graft-versus-host disease prevention, and conditioning strategies can help improve transplant outcomes. The discussion also explores the role of real-world evidence in identifying best practices and supporting efforts to harmonize transplantation approaches across centres.  

Dr Gagelmann also highlights the evolving role of CAR T-cell therapy, ongoing disparities in access to innovative treatments, and the importance of collaboration, education, and knowledge sharing across countries. He reflects on building international professional communities, addressing inequalities in hematology care, and ensuring that future advances remain accessible to patients. Listen now for insights into the future of transplantation, cellular therapies, and global hematology collaboration.

Guest: Dr Nico Gagelmann, Dana-Farber Cancer Institute, Boston, Massachusetts, USA, and University Medical Center Hamburg-Eppendorf, Germany

Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer  

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, Prof George Vassiliou, recipient of the 2026 EHA Research Excellence Award, discusses how his research has advanced our understanding of clonal haematopoiesis and its relationship to acute myeloid leukaemia (AML). He explains how blood stem cells evolve over time, why specific driver mutations promote clonal expansion, and how genetic profiles can help identify individuals at low, intermediate, or high risk of developing myeloid malignancies.  

The discussion also explores efforts to translate these discoveries into clinical prevention strategies. Prof Vassiliou highlights emerging risk prediction models, the development of clinics focused on clonal haematopoiesis, and ongoing work to evaluate low-toxicity interventions that could reduce disease progression. He also examines the links between clonal haematopoiesis, cardiovascular disease, immune ageing, and age-related health outcomes, offering insights into the future of early detection and preventive approaches in haematology. Listen now for perspectives on how understanding clonal haematopoiesis may help reshape the prevention of AML and other age-related diseases.  

Guest: Prof George Vassiliou, Department of Haematology and Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom 

Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer  

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, EHA 2026 Lifetime Achievement Award recipient Prof Claire Harrison reflects on a career dedicated to advancing the understanding and management of myeloproliferative neoplasms (MPNs). She reviews the major scientific and clinical developments she has witnessed over more than two decades, including the discovery of JAK2, MPL and CALR mutations, the evolution of diagnostic criteria, and the emergence of targeted therapies for MPNs. 

The discussion explores landmark studies that helped shape current clinical practice, including PT-1, COMFORT-II and MAJIC-PV, as well as the growing role of patient advocacy in driving research and improving care. Prof Harrison also looks ahead to the next generation of therapies, including CALR-targeted immune approaches and combination treatment strategies, while highlighting the challenges and opportunities that remain for patients with MPNs. Listen now for insights from one of the leading figures in the field.

Guest: Prof Claire Harrison 

Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom 

Host: Isabel Olivera-Martínez, PhD, EHA Medical Writer  

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In this episode, Dr Annalisa Ruggeri discusses how registry data are helping clinicians better understand, monitor and manage CAR T-related toxicities. She explains how insights from more than 16,000 patients recorded in the European Bone Marrow Transplant Registry (EBMT), have helped improve early toxicities such as cytokine release syndrome (CRS) and ICANS awareness and management as well as helped recognise and address longer-term effects. She further explores the growing understanding of immune effector cell-associated hematotoxicity (ICAHT) and the importance of risk prediction and early intervention.  

Dr Ruggeri also discusses emerging safety questions as CAR T use expands, including secondary malignancies, long-term immune effects, and fertility outcomes. She highlights encouraging registry findings showing that fertility recovery and successful pregnancies are possible after CAR T therapy, offering renewed hope for patients seeking to return to normal life following treatment. Listen now for valuable insights into how registries, collaboration and long-term follow-up are helping improve cellular therapy.

Guest: 

Dr Annalisa Ruggeri 

Haematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy 

Chair of the Cellular Therapy and Immunobiology Working Party (Education Portfolio), EBMT

Host: Leah DeLeon 

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In the final episode of our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM), we explore how the meeting acts as a powerful launching pad for scientific careers. We talk to 2018 YERM speakers Dr. Lorena Arranz and Dr. Mattias Carlsten to hear about their experiences presenting their research at YERM. Looking back on their journeys, they share valuable advice and lessons learned at YERM to help guide today's early-career researchers.
Guests: 

Dr Mattias Carlsten, Karolinska Institutet and Karolinska University Hospital, Sweden  

Dr. Lorena Arranz, University of Oslo and Oslo University Hospital, Oslo, Norway 

Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Welcome to our mini-series celebrating the 10th anniversary of the Young EHA Research Meeting (YERM) with an introduction to its history and mission. We sit down with co-founder Prof Ruud Delwel and current organizer Prof Marlies Vanden Bempt to discuss how YERM is tailored to empower early-career researchers. Together, we reflect on a decade of growth and share their vision for the future of YERM. 

Guests: 

Prof Ruud Delwel, Erasmus Medical Centre, The Netherlands

Prof Marlies Vanden Bempt, KU Leuven, Belgium

Host: Rhiannon Newman, MSc, University of Helsinki and Young EHA committee

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Provide Feedback⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://ehaedu.org/Campus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/EHA_Hematology/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://e-h-a.link/facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.linkedin.com/company/eha/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eha.news/subscribe⁠⁠⁠⁠⁠⁠⁠⁠⁠